Laura Cogrossi (@lauracgr001) 's Twitter Profile
Laura Cogrossi

@lauracgr001

Science explorer in Immunology 🔬 PhD Student @Bellone_lab @myunisr @sanraffaelemi

ID: 1285644271270404096

calendar_today21-07-2020 18:34:22

38 Tweet

50 Followers

169 Following

Mike Thompson, MD, PhD, FASCO (@mtmdphd) 's Twitter Profile Photo

Exploiting the Gut Microbiota to Boost Immunotherapy and Switch the Trajectory of Multiple Myeloma [Mon, Dec 11, 2023: 11:15a] Laura Cogrossi et al. #ASH23 Abst 754 ash.confex.com/ash/2023/webpr… #IDonc #ImmunoOnc #mmsm

Laura Cogrossi (@lauracgr001) 's Twitter Profile Photo

“We are not alone” reminders at #ASH2023 Terrific session about gut microbiota and hematological malignancies this morning

“We are not alone” reminders at #ASH2023 
Terrific session about gut microbiota and hematological malignancies this morning
Laura Cogrossi (@lauracgr001) 's Twitter Profile Photo

It has been a great honor to present our work about #microbiota and #immunotherapy preventing the progression of #MM #SMM at #ASH2023! New connections and new interesting interactions! Thanks ASH and CellularImmune_lab for the support

Laura Cogrossi (@lauracgr001) 's Twitter Profile Photo

Most important slide of my presentation at divisional #DITID #retreat in Brescia! As always thank to CellularImmune_lab and happy to share new perspectives going on in our division Ospedale San Raffaele

Most important slide of my presentation at divisional #DITID #retreat in Brescia! As always thank to <a href="/Bellone_lab/">CellularImmune_lab</a> and happy to share new perspectives going on in our division <a href="/SanRaffaeleMI/">Ospedale San Raffaele</a>
Nature Medicine (@naturemedicine) 's Twitter Profile Photo

Understanding the dynamics of the gut #Microbiota over the course of #Cancer treatment regimens and their associated adverse events can help identify microbial features that associate with response to immune checkpoint blockade. nature.com/articles/s4159…

Nature Portfolio (@natureportfolio) 's Twitter Profile Photo

A paper in Nature Medicine reports on efforts to identify microbial signatures of response to immune checkpoint blockade that suggest that strain-level associations may be cancer type agnostic but cancer therapy specific. go.nature.com/3V2JgLx

A paper in <a href="/NatureMedicine/">Nature Medicine</a> reports on efforts to identify microbial signatures of response to immune checkpoint blockade that suggest that strain-level associations may be cancer type agnostic but cancer therapy specific. go.nature.com/3V2JgLx
Urvi Shah (@urvishahmd) 's Twitter Profile Photo

Growing evidence shows that dietary interventions can be effective at treating or delaying some diseases, but further trials are needed for wider adoption (especially in cancer) Nature Medicine nature.com/articles/s4159…

Andrea Necchi (@andreanecchi) 's Twitter Profile Photo

Out in Journal of Clinical Oncology our next piece of the neoadjuvant puzzle in muscle-invasive #bladdercancer. Taxanes could be another good choice of backbone chemo to combine with IO, overcoming the known limits of platinum. #NureCombo provided Nivo/ABX x4 > RC > adj Nivo x13. N=31. 22 pts

Andrea Necchi (@andreanecchi) 's Twitter Profile Photo

Pts with an ypT0N0 response had lower baseline fraction of PMN cells (CD15+CD45+) compared to ypT</=1N0 responders and nonresponders (ypT≥2N0 and ypN+) Longitudinal analyses showed that at C2D1 the fraction of CD11b+CD33+CD14+HLA-DRlow/int monocytic myeloid cells increased in

Pts with an ypT0N0 response had lower baseline fraction of PMN cells (CD15+CD45+) compared to ypT&lt;/=1N0 responders and nonresponders (ypT≥2N0 and ypN+)
Longitudinal analyses showed that at C2D1 the fraction of CD11b+CD33+CD14+HLA-DRlow/int monocytic myeloid cells increased in
Laura Cogrossi (@lauracgr001) 's Twitter Profile Photo

Novel data finally out on muscle-invasive #bladdercancer #neoadjuvant therapy. Glad to have contributed to #immunebiomarker analysis ⁦CellularImmune_lab⁩ ⁦Andrea Necchi⁩ ascopubs.org/doi/10.1200/JC…

Giovanni Pastorino (@gio_pasto_real) 's Twitter Profile Photo

Finally out!! Neoadjuvant Nivo + ABX with 35.7% pCR and nearly 70% pMR in MIBC regardless of platinum eligibility. Lower PB fraction of PMN-MDSCs and intermediate monocyte in pCR but at baseline only. CD11b+CD33hi monos increase from baseline to C2D1. Next step: SG +/- Pembro

Finally out!! Neoadjuvant Nivo + ABX with 35.7% pCR and nearly 70% pMR in MIBC regardless of platinum eligibility. Lower PB fraction of PMN-MDSCs and intermediate monocyte in pCR but at baseline only. CD11b+CD33hi monos increase from baseline to C2D1. Next step: SG +/- Pembro
Laura Cogrossi (@lauracgr001) 's Twitter Profile Photo

Excited to share results from Nutrivention trial and mouse study to prevent progression from #smm to #myeloma at #cicon24 in Washington DC. Great environment and shared interest in cancer #immunotherapy. Acknowledgments to ⁦Urvi Shah⁩ leading the clinical study.

Excited to share results from Nutrivention trial and mouse study to prevent progression from #smm to #myeloma at #cicon24 in Washington DC. Great environment and shared interest in cancer #immunotherapy. Acknowledgments to ⁦<a href="/UrviShahMD/">Urvi Shah</a>⁩ leading the clinical study.
Laura Cogrossi (@lauracgr001) 's Twitter Profile Photo

Honored to be selected to share our work during #diet and #microbiota session with amazing speakers. #FMT, #microbiota-based therapies and #nutrition the novel pillars for cancer prevention and immunotherapy #Cicon24 Cancer Research Institute

Laura Cogrossi (@lauracgr001) 's Twitter Profile Photo

Today’s issue of The Washington Post The Washington Post keeps up with #cicon24 topics! #fibers plant-based #diet. Perfect meeting conclusion just before takeoff

Today’s issue of The Washington Post <a href="/TheWashingtonPo/">The Washington Post</a> keeps up with #cicon24 topics! #fibers plant-based #diet. Perfect meeting conclusion just before takeoff
Journal of Clinical Oncology (@jco_asco) 's Twitter Profile Photo

First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive #BladderCancer brnw.ch/21wMC1Y Andrea Necchi #blsm